MA-BLUECONIC
9.7.2020 15:07:09 CEST | Business Wire | Press release
BlueConic, the world’s leading pure-play customer data platform (CDP), today announced enhancements to its best-in-class lifecycle orchestration capabilities, which enable marketers to move beyond channel-specific campaign workflows and instead, orchestrate cross-channel lifecycle marketing programs that are responsive to each customer’s unique journey based on the real-time, unified customer profile data at the platform’s core.
Customers are fully in control of when and where they interact with any given brand. It falls on marketers to deliver relevant and valuable experiences in every customer lifecycle stage, while also being responsive to changes in their interests, behaviors, and privacy preferences along the way. But traditional marketing technologies have fallen short in their ability to deliver or suppress messaging based on a full understanding of the customer at every point in their journey. To effectively orchestrate individualized experiences throughout the customer lifecycle, marketers and their activation technologies, such as campaign management platforms, ESPs, and personalization engines, need access to a single customer view in the form of a unified customer profile that offers the confidence and utility to act in real-time based on data from across the journey.
With unified customer profiles as the foundation, BlueConic’s lifecycle orchestration capabilities provide access to the real-time data marketers need to improve the outcomes of their cross-channel, customer lifecycle programs. The fully configurable capability frees marketers from the limitations of rigid, rules-based campaign workflows in their activation technologies by enabling them to organize, coordinate, and visualize all of the cross-channel marketing touchpoints used to influence and advance individuals from one lifecycle stage to the next.
Using the platform’s marketer-friendly interface, users can:
- Define any number of customer lifecycles , each consisting of sequential, mutually exclusive stages that share a common marketing goal, whether it’s influencing target individuals to become a customer, make a second purchase, or upgrade a plan, as examples
- Understand an individual’s attributes and behaviors at any given time to determine their eligibility to enter a particular lifecycle or lifecycle stage
- Align cross-channel touchpoints in each stage behind the common objective of advancing customers or prospects to the next stage in the lifecycle
- Leverage connections with existing marketing activation technologies to direct them to trigger or suppress messaging to individuals within each stage of the lifecycle
- Pass stage data to any analytics platform to further analyze performance and audiences
“BlueConic’s enhanced customer lifecycle orchestration capabilities fulfill the promise of unified, actionable first-party data by filling the gaps of legacy marketing activation technologies. Unlike campaign management tools that were built for static, outbound campaigns based on a limited understanding of the individual, our platform provides a comprehensive, accurate, cross-channel understanding of the individual and their journey,” said Bart Heilbron, founder and chief executive officer at BlueConic. “Our customers can also act on the data to improve their marketing programs because our platform provides the intelligence they are missing in their other technologies to target or suppress messaging at an individual level in a more impactful way.”
For more information, please visit https://www.blueconic.com/customer-data-platform/customer-lifecycle-orchestration/ .
About BlueConic
BlueConic, the world’s leading customer data platform, liberates marketers’ first-party data from all the disparate systems in which it exists, and makes it accessible wherever and whenever it is required from marketing. More than 300 consumer and B2B brands, including Hearst Newspapers, Moen, T-Mobile, ING, America’s Test Kitchen, and Franklin Sports, leverage BlueConic to unify their first-party customer data into persistent, person-level profiles, and then activate it across their marketing ecosystem. Founded in 2010, the company is headquartered in Boston, with offices in Europe. Learn more at www.blueconic.com and follow us on Twitter and LinkedIn @BlueConic.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005255/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom